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Abstract
Purpose—Tools to estimate survival, such as ePrognosis (http://eprognosis.ucsf.edu/carey2.php), 
were developed for general, not cancer, populations. In older patients with breast cancer, accurate 
overall survival estimates would facilitate discussions about adjuvant therapies.
Methods—Secondary analyses were performed of data from two parallel breast cancer studies 
(CALGB/Alliance 49907/NCT000224102 and CALGB/Alliance 369901/NCT00068328). We 
included patients (n=971) who were age 70 years and older with complete baseline quality of life 
data (194 from 49907; 777 from 369901). Estimated versus observed all-cause two-year mortality 
rates were compared. ePrognosis score was calculated based on age, sex, and daily function 
(derived from EORTC QLQ-C30). ePrognosis scores range from 0 to 10, with higher scores 
indicating worse prognosis based on mortality of community-dwelling elders, and were 
categorized into three groups (0–2, 3–6, 7–10). Observed mortality rates were estimated using 
Kaplan-Meier methods.
Results—Patient mean age was 75.8 years (range 70–91) and 73% had stage I-IIA disease. Most 
patients were classified by ePrognosis as good prognosis (n=562, 58% 0–2) and few (n=18, 2% 7–
10) poor prognosis. Two-year observed mortality rates were significantly lower than ePrognosis 
estimates for patients scoring 0–2 (2% vs 5%, p=0.001) and 3–6 (8% vs 12%, p=0.01). The same 
trend was seen with scores of 7–10 (23% vs 36%, p=0.25).
Conclusions—ePrognosis tool only modestly overestimates mortality rate in older breast cancer 
patients enrolled in two cooperative group studies. This tool, which estimates non-cancer mortality 
risk based on readily available clinical information, may inform adjuvant therapy decisions, but 
should be validated in non-clinical trial populations.
Keywords
Breast cancer; survival estimates; ePrognosis; elderly
INTRODUCTION
Cancer systemic adjuvant therapy prevents future distant recurrences and improves long-
term survival.[1] In older patients, the balance of benefits and risks of cancer treatment is 
complicated by competing causes of mortality, presence of frailty, and advanced age. These 
factors are associated with increase treatment toxicity and limited overall and cancer-specific 
survival and, therefore, hinder discussions about preventive therapies and participation in 
clinical trials.[2,3] Data on life expectancy could support treatment decision-making.
Several extant tools are available to estimate life expectancy in older individuals and they are 
compiled for clinical use in ePrognosis (http://eprognosis.ucsf.edu/).[4] The ePrognosis tools 
were designed for older adults without severe illnesses, such as cancer, and are validated in 
community-dwelling, nursing-home, or hospitalized older individuals. None of these indices 
is validated in patients with non-metastatic cancer, who might be considering potentially 
curative adjuvant therapies.
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We conducted a secondary analysis of data from two cancer cooperative group studies to 
compare short-term (two-year) ePrognosis estimated versus observed all-cause mortality 
rates among older women with non-metastatic breast cancer. Studies included were (1) a 
phase III, randomized study of adjuvant chemotherapy for breast cancer in women age 65 
years and older (CALGB 49907/NCT000224102)[5] and (2) a parallel observational study 
with the same eligibility criteria (CALGB 369901/NCT00068328)[6]. CALGB is now a part 
of the Alliance for Clinical Trials in Oncology. By design, the two studies included a 
common core of sociodemographic and quality of life data.[7]
METHODS
This study was deemed exempt by the Duke University Hospital System Institutional 
Review Board.
Patients with early-stage breast cancer participating in CALGB/Alliance 49907 and 369901, 
who were age 70 years and older and had completed baseline quality of life questionnaires, 
were included in the analysis (Figure 1). Age 70 years was chosen to parallel ePrognosis. 
We selected two-year all-cause mortality because short-term limits in life expectancy would 
have a large influence on systemic therapy decisions, particularly among women with 
estrogen-receptor negative. Cause of death was grouped as breast cancer-related and other, 
which included unknown cause.
Estimations of Prognosis
The two-year ePrognosis tool[8] was developed from the Asset and Health Dynamics 
Among the Oldest Old (AHEAD) study of 4516 community dwelling adults, age 70 years 
and older, and provides mortality estimates based on answers to six function questions. We 
matched data items collected from the European Organization for Research and Treatment 
of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30) at baseline to the ePrognosis 
tool.
The ePrognosis tool assigns a score to each item, for a summary score ranging from 1–10, 
with zero indicating the best prognosis. We applied the scoring system to the study data as 
follows:
1. “How old is your patient?” Age was available in both studies and was scored as 0 
if age 70–75, 1 if age 76–80, and 2 if age >80.
2. “What is your patient’s sex?” All patients were female and were score as 0.
3. “Does your patient need help from another person to bathe?” Defined from the 
question “do you need help with eating, dressing, washing yourself, or using the 
toilet?” on the EORTC QLQ-C30. Scored as 0 if answered “not at all”, otherwise 
1 point.
4. “Does your patient need help from another person to shop for groceries?” 
Defined from the EORTC QLQ-C30: During the past week, were you limited in 
doing either your work or other daily activities? Scored as 0 if answered “not at 
all”, otherwise 2 points.
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5. “Does your patient have difficulty walking several blocks?” Defined from the 
EORTC QLQ-C30: Do you have any trouble taking a long walk? Scored as 0 if 
answered “not at all”, otherwise 2 points.
6. “Does your patient have difficulty pushing or pulling a heavy object, such as an 
arm chair?” Defined from the EORTC QLQ-C30: Have you felt weak? Scored as 
0 if answered “not at all”, otherwise 1 point.
Statistical Analysis
Observed all-cause mortality rates (and 95% confidence intervals) were calculated for both 
samples combined and each protocol separately from study entry to death using Kaplan-
Meier methods.[9,10] All-cause mortality rates were also calculated for each stratum of the 
ePrognosis score categories (0–2 points, 3–6 points, and 7–10 points). Observations were 
censored at the date last known alive. The two-year survival Index scores from ePrognosis 
were used to generate an estimated survival rate for each score category. A two-sided z-test 
was used to compare the observed versus estimated mortality rates. Data collection and 
statistical analyses were conducted by the Alliance Statistical and Data Center. All analyses 
were conducted using SAS Version 9.4 (SAS Institute, Cary, NC, USA) on a dataset locked 
on May 15, 2015.
RESULTS
Participant mean age was 76 years with range of 70–91 years. Patient characteristics, overall 
and by study, are presented in Table 1. Of those that died within 2 years, 55% died from 
causes related to breast cancer. Most women were in the good prognosis category (n=562, 
58%) and 18 (2%) in the poor prognosis category.
Predicted and observed mortality estimates by ePrognosis are shown in Table 2 and 
Appendix Figure 1. Two-year observed mortality was significantly lower than estimated 
from ePrognosis for patients scoring 0–2 (2% vs 5%, p=0.001) and 3–6 (8% vs 12%, 
p=0.01) points. Although not significant, the same trend was seen for the small number with 
scores of 7–10 (23% vs 36%, p=0.25).
The results are similar within each study (Appendix Table 1 and Figures 2 and 3).
DISCUSSION
Older women with non-metastatic breast cancer participating in cooperative group studies 
have very low two-year all-cause mortality rates. The ePrognosis tool systematically, but 
only slightly, over-estimated mortality. This may have implications for practice, since the 
tool may be used by clinicians when discussing systemic treatment options that have short-
term toxicity but long-term benefits in preventing recurrence.[1]
These results are consistent with studies of linked SEER-Medicare datasets showing that 
women age 65 years and older with early-stage breast cancer have higher non-breast cancer 
survival than matched women without breast cancer.[11,12] Higher socio-economic status, 
healthier behaviors, better healthcare access, and more routine doctor visits to treat 
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coexisting illness are thought to explain the better non-breast cancer survival seen in older 
breast cancer patients.[11,13,14] Use of older datasets to derive ePrognosis estimates and 
lower mortality over time due to improvements in management of acute toxicities and 
comorbidities may also explain why ePrognosis provided an overestimate.[15] Interestingly, 
other online prognostic tools, such as Adjuvant! Online and PREDICT, slightly over-
estimate 10-year survival.[16,17]
This study is limited by the secondary nature of the analysis, some non-correspondence 
between items on the tool and those available from EORTC, and use of cooperative group 
data. These results will need to be confirmed in broader, older breast cancer populations and 
community settings. However, the prospective design of the original studies, high quality of 
data collection, and inclusion of many community hospitals and observational data enhances 
the generalizability of the finding.
Despite these caveats, the results were robust across data sets and prognostic groups and 
suggest that tools developed in general populations provide a slight overestimate of mortality 
in older breast cancer patients, which may not be clinically significant. Even so, 
development and testing of more accurate tools to estimate mortality in older breast cancer 
patients could enhance shared decision-making about the risks and benefits of adjuvant 
therapies.
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Appendix
Appendix Figure 1. 
Observed 2-year Survival by ePrognosis Category
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Appendix Figure 2. 
Observed 2-year Survival among CALGB/Aliance 49907 Patients by ePrognosis Category
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Appendix Figure 3. 
Observed 2-year Survival among CALGB/Alliance 369901 Patients by ePrognosis Category
Appendix Table 1
Predicted vs. Observed 2-year All-Cause Mortality Rates in a Sample of Non-Metastatic 
Breast Cancer Patients Ages 70 years and Older by Study
ePrognosis Prediction 49907 Patients 369901 Patients
Points Predicted 
Probability 
of Survival
N Number of Deaths Observed 
Probability of 
Overall 
Survival at 2 
years (%, 95% 
CI)
p-value N Number of Deaths Observed 
Probability 
of Overall 
Survival at 
2 years (%, 
95% CI)
p-value
0–2 5% 92 0 0% 0.03 470 12 3% (1–4%) 0.047
3–6 12% 95 9 10% (5–18%) 0.55 296 24 8% (6–12%) 0.03
7–10 36% 7 3 43% (26–83%) 0.70 11 1 9% (1–49%) 0.06
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Figure 1. 
Sample derivation and number of events.
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Table 1
Characteristics of Non-Metastatic Breast Cancer Patients ages 70+ Enrolled in Two CALGB/Alliance 
Protocols
Characteristic Total
(N=971)
49907
(N=194)
369901
(N=777)
p-value
Years of enrollment 2001–2006 2004–2011
Median follow-up (years)
range
6.67
(0, 12.6)
8.17
(0, 12.61)
6.59
(0.14, 10.75)
Age, (years) mean (SD)
range
70–75
76–80
>80
75.8 (4.6)
(70, 91)
535 (55.1%)
287 (29.6%)
149 (15.3%)
74.6 (3.7)
(70, 89)
124 (63.9%)
57 (29.4%)
13 (6.7%)
76.1 (4.7)
(70, 91)
411 (52.9%)
230 (29.6%)
136 (17.5%)
0.0002
0.001
ECOG Performance status
0
1
2
Missing
131 (67.5%)
59 (30.4%)
4 (2.1%)
Not Available
Race or ethnic group
 White
 Black or African American
 Other
 Unknown
863 (88.9%)
88 (9.1%)
15 (1.5%)
5 (<1%)
166 (85.6%)
23 (11.9%)
3 (1.5%)
2(1.0%)
697 (89.7%)
65 (8.4%)
12 (1.5%)
3 (0.4%)
0.30
Ethnicity
 Hispanic or Latino
 Non-Hispanic
 Unknown/Not reported
18 (1.8%)
936 (96.4%)
18 (1.8%)
4 (2.0%)
178 (91.8%)
12 (6.2%)
14 (1.8%)
758 (97.4%)
6 (<1%)
0.74
Tumor size
 ≤ 2 cm
 > 2 to ≤ 5 cm
 > 5 cm
 Missing
560 (57.7%)
365 (37.6%)
43 (4.4%)
3 (<1%)
76 (39.2%)
107 (55.2%)
10 (5.2%)
1 (< 1%)
484 (62.3%)
258 (33.2%)
33 (4.2%)
2 (<1%)
<0.0001
No. of positive lymph nodes
 0
 1–3
 4–9
 ≥ 10
 Missing
308 (31.7%)
218 (22.5%)
89 (9.2%)
52 (5.3%)
304 (31.3%)
51 (26.3%)
104 (53.6%)
31 (16.0%)
7 (3.6%)
1 (< 1%)
257 (33.1%)
114 (14.7%)
58 (7.5%)
45 (5.8%)
303 (39.0%)
<0.0001
ER Positive status
 Negative
 Positive
 Missing
210 (21.6%)
760 (78.3%)
1 (<1%)
80 (41.2%)
114 (58.8%)
0
130 (16.7%)
646 (83.1%)
1 (<1%)
<0.0001
HER2 status
 Negative
 Positive
 Unknown
155 (79.9%)
29 (14.9%)
10 (5.2%)
Not available
Type of surgery
 Partial mastectomy/lumpectomy/excisional bx
 Mastectomy/NOS
 Missing
589 (60.7%)
381 (39.2%)
2(<1%)
80 (41.2%)
113 (58.2%)
1 (< 1%)
509 (65.5%)
268 (34.4%)
1 (<1%)
<0.0001
Axillary evaluation
 Sentinel-node biopsy only
 Axillary dissection only
 Sentinel-node biopsy and axillary dissection
 Neither sentinel-node nor axillary dissection
 Missing
311 (32.0%)
208 (21.4%)
387 (40.0%)
64 (6.6%)
1 (<1%)
0
71 (36.6%)
87 (44.8%)
35 (18.0%)
1 <1%)
311 (40.0%)
137 (17.6%)
300 (38.6%)
29 (3.7%)
0
<0.0001
Adjuvant chemotherapy
 Chemotherapy
 No Chemotherapy
 Not reported/Unknown
442 (45.5%)
492 (50.7%)
37 (3.8%)
194 (100%)
0
0
248 (31.9%)
492 (63.3%)
37 (4.8%)
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Characteristic Total
(N=971)
49907
(N=194)
369901
(N=777)
p-value
AJCC Stage
  Stage I
  Stage IIA
  Stage IIB
  Stage IIIA
  Stage IIIB
  Stage IIIC
  Missing
380 (40.2%)
308 (32.6%)
159 (16.8%)
67 (7.1%)
6 (0.6%)
25 (2.6%)
26 (2.7%)
18 (10.7%)
67 (39.6%)
68 (40.2%)
14 (8.3%)
0 (0.0%)
2 (1.2%)
25 (12.9%)
362 (46.6%)
241 (31.1%)
91 (11.7%)
53 (6.8%)
6 (0.8%)
23 (3.0%)
1 (<1%)
<0.0001
Cause of Death
  Breast Cancer-related Cause
  Other Cause
27 (55.1%)
22 (44.9%)
7 (58.3%)
5 (41.7%)
20 (54.1%)
17 (45.9%)
0.796
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